Biodesix, Inc. BDSX

NASDAQHealth ServicesUnited States

$9.88+0.09 (+0.92%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 9.8511.32
52-week range: 5.2631.97

Financial health

– / 5

Analyst view · 7 firms

Buy7 buy · 0 hold · 0 sell

Avg. target $32.17 (+225.6%)

Prices may be delayed and are for informational purposes only - not investment advice.

Biodesix, Inc. BDSX

NASDAQHealth ServicesUnited States

$9.88+0.09 (+0.92%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 9.8511.32
52-week range: 5.2631.97

Financial health

– / 5

Analyst view · 7 firms

Buy7 buy · 0 hold · 0 sell

Avg. target $32.17 (+225.6%)

Valuation from filings

Calculated from the tables below and the current price ($9.88) · LTM · 2026/9 · 2026-09-30

P/E: —EPS $-2.76
P/B: 11.62BV/share $0.85
P/S: 0.96Sales/share $10.31
Return on equity: -312.1%Net income / equity
Net margin: -25.7%Operating margin -18.7%
Free cash flow yield: -17.4%Free cash flow / market cap

Revenue and net income

Fiscal year · $ millions · net margin below

RevenueNet Income

Financial statements

$ thousands · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2021	2022	2023	2024	2025	LTM
Income Statement
Revenue	54,506	38,212-30%	49,087+28%	71,323+45%	88,499+24%	105,212
Operating expenses
Operating Income
EBITDA
Income tax (expense) / benefit
Net Income	(43,159)	(65,447)+52%	(52,146)-20%	(42,931)-18%	(35,265)-18%	(27,078)
Earnings per share ($)
Margins
Operating margin
EBITDA margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.